Here are three things to know:
1. Ortho RTi’s proprietary platform consists of the biopolymer chitosan, which is intended to be directly placed into the injury site during routine operative procedures.
2. The company develops treatments for rotator cuff and meniscus injuries.
3. The company issued a total of 450,000 Class “A” shares pursuant to the second tranche of its previously announced non-brokered private placement.
More articles on biologics:
23 developments in spine & orthopedic biologics research in 2018
3 things to know about AlloSource
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
